Search

Your search keyword '"Barry Skikne"' showing total 2 results
Start Over Author "Barry Skikne" Journal journal of hematology & oncology
2 results on '"Barry Skikne"'

1. Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

Author

Farhad Ravandi, Gail J. Roboz, Andrew H. Wei, Hartmut Döhner, Christopher Pocock, Dominik Selleslag, Pau Montesinos, Hamid Sayar, Maurizio Musso, Angela Figuera-Alvarez, Hana Safah, William Tse, Sang Kyun Sohn, Devendra Hiwase, Timothy Chevassut, Francesca Pierdomenico, Ignazia La Torre, Barry Skikne, Rochelle Bailey, Jianhua Zhong, C. L. Beach, and Herve Dombret

Subjects
Oral azacitidine, CC-486, Safety, Maintenance, Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Most older patients with acute myeloid leukemia (AML) who attain morphologic remission with intensive chemotherapy (IC) will eventually relapse and post-relapse prognosis is dismal. In the pivotal QUAZAR AML-001 trial, oral azacitidine maintenance therapy significantly prolonged overall survival by 9.9 months (P

Published
2021
Full Text
View/download PDF

2. Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)

Author

Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, Odile Beyne-Rauzy, Moshe Mittelman, Petra Muus, Stephen D. Nimer, Eva Hellström-Lindberg, Bayard L. Powell, Agnes Guerci-Bresler, Mikkael A. Sekeres, H. Joachim Deeg, Consuelo del Cañizo, Peter L. Greenberg, Jamile M. Shammo, Barry Skikne, Xujie Yu, and Alan F. List

Subjects
Acute myeloid leukemia, del(5q), Lenalidomide, Myelodysplastic syndromes, Age, Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Particularly since the advent of lenalidomide, lower-risk myelodysplastic syndromes (MDS) patients with del(5q) have been the focus of many studies; however, the impact of age on disease characteristics and response to lenalidomide has not been analyzed. Methods We assessed the effect of age on clinical characteristics and outcomes in 286 lenalidomide-treated MDS patients with del(5q) from two multicenter trials. Results A total of 33.9, 34.3, and 31.8% patients were aged

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results